« Return to News | R&D Trends

OrbiMed launches $222 million fund in Israel life sciences

Tuesday, April 24, 2012 12:18 PM

OrbiMed, a global investment management firm focused on the healthcare sector, has closed its first investment fund dedicated to life sciences venture capital opportunities based in Israel. The Fund, OrbiMed Israel Partners Limited Partnership, includes an anchor investment provided by the government of Israel, which also provided special economic terms through the initial tender process for the Fund.

OrbiMed Israel Partners is led by three full-time Israel-based partners, Dr. Nissim Darvish, Anat Naschitz and Erez Chimovits.

 OrbiMed Israel builds on OrbiMed's longstanding investment interest in Israel, which has led to multiple investments over the past decade, including early-stage investments in Given Imaging and SuperDimension (acquired by Covidien).

Dr. Darvish, senior managing director at OrbiMed Israel, said the new fund invests in biotechnology, pharmaceutical, medical device and diagnostics companies at varying stages of maturity, from seed stage through growth equity. It already has made two investments: Keystone Heart, developing an embolic protection device for interventional cardiology procedures, and Otic Pharma, developing foam formulations for ear medication.

OrbiMed is dedicated exclusively to the life sciences sector, with approximately $6 billion in assets under management. It invests across pharmaceutical, biotechnology and medical device companies worldwide, with offices in New York City, Tel Aviv, San Francisco, Shanghai and Mumbai.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.